Determining the Role of Cystectomy for High-grade T1 Urothelial Carcinoma

Urologic Clinics of North America

Volumn 40, Issue 2, 2013, Pages 233-247

  Daneshmand, Siamak ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

BCG; Bladder cancer; Cystectomy; High grade; T1; T1G3; Treatment

Indexed keywords

BCG VACCINE; CYCLOOXYGENASE 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; KI 67 ANTIGEN; MITOMYCIN; NUCLEAR MATRIX PROTEIN 22; PROTEIN P53;

CANCER GRADING; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONSERVATIVE TREATMENT; CYSTECTOMY; CYSTOSCOPY; EARLY INTERVENTION; HISTOPATHOLOGY; HUMAN; LOCAL RECURRENCE FREE SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; SURVIVAL TIME; THERAPY DELAY; TRANSITIONAL CELL CARCINOMA; TREATMENT INDICATION; TUMOR INVASION; TUMOR LOCALIZATION; TUMOR VOLUME;

CARCINOMA, TRANSITIONAL CELL; COMBINED MODALITY THERAPY; CYSTECTOMY; DISEASE PROGRESSION; HUMANS; NEOPLASM GRADING; NEOPLASM STAGING; URINARY BLADDER NEOPLASMS;

EID: 84876695823     PISSN: 00940143     EISSN: 1558318X     Source Type: Journal    
DOI: 10.1016/j.ucl.2013.01.003     Document Type: Review

References (112)

1. van Rhijn B.W., Burger M., Lotan Y., et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol 2009, 56:430-442.
2. Cookson M.S., Herr H.W., Zhang Z.F., et al. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 1997, 158:62-67.
3. Heney N.M., Ahmed S., Flanagan M.J., et al. Superficial bladder cancer: progression and recurrence. J Urol 1983, 130:1083-1086.
4. Herr H.W., Schwalb D.M., Zhang Z.F., et al. Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J Clin Oncol 1995, 13:1404-1408.
5. Bianco F.J., Justa D., Grignon D.J., et al. Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy. Urol Oncol 2004, 22:290-294.
6. Esrig D., Freeman J.A., Stein J.P., et al. Early cystectomy for clinical stage T1 transitional cell carcinoma of the bladder. Semin Urol Oncol 1997, 15:154-160.
7. Skinner E.C. The best treatment for high-grade T1 bladder cancer is cystectomy. Urol Oncol 2007, 25:523-525.
8. Lambert E.H., Pierorazio P.M., Olsson C.A., et al. The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy. BJU Int 2007, 100:33-36.
9. Luciani L.G., Neulander E., Murphy W.M., et al. Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer: an investigational approach. Urology 2001, 58:376-379.
10. O'Donnell M.A., Lilli K., Leopold C. Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer. J Urol 2004, 172:888-893.
11. Van Der Meijden A., Sylvester R., Collette L., et al. The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: a combined analysis of 5 European Organization for Research and Treatment of Cancer trials. J Urol 2000, 164:1533-1537.
12. Mark J.R., Gelpi-Hammerschmidt F., Trabulsi E.J., et al. Blue light cystoscopy for detection and treatment of non-muscle invasive bladder cancer. Can J Urol 2012, 19:6227-6231.
13. Dutta S.C., Smith J.A., Shappell S.B., et al. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol 2001, 166:490-493.
14. Herr H.W. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 1999, 162:74-76.
15. Jancke G., Rosell J., Jahnson S. Residual tumour in the marginal resection after a complete transurethral resection is associated with local recurrence in Ta/T1 urinary bladder cancer. Scand J Urol Nephrol 2012, 46:343-347.
16. Orsola A., Trias I., Raventos C.X., et al. Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients. Eur Urol 2005, 48:231-238. [discussion: 238].
17. Platz C.E., Cohen M.B., Jones M.P., et al. Is microstaging of early invasive cancer of the urinary bladder possible or useful?. Mod Pathol 1996, 9:1035-1039.
18. Holmang S., Hedelin H., Anderstrom C., et al. The importance of the depth of invasion in stage T1 bladder carcinoma: a prospective cohort study. J Urol 1997, 157:800-803. [discussion: 804].
19. Smits G., Schaafsma E., Kiemeney L., et al. Microstaging of pT1 transitional cell carcinoma of the bladder: identification of subgroups with distinct risks of progression. Urology 1998, 52:1009-1013. [discussion: 1013-4].
20. Younes M., Sussman J., True L.D. The usefulness of the level of the muscularis mucosae in the staging of invasive transitional cell carcinoma of the urinary bladder. Cancer 1990, 66:543-548.
21. Angulo J.C., Lopez J.I., Grignon D.J., et al. Muscularis mucosa differentiates two populations with different prognosis in stage T1 bladder cancer. Urology 1995, 45:47-53.
22. van Rhijn B.W., van der Kwast T.H., Alkhateeb S.S., et al. A new and highly prognostic system to discern T1 bladder cancer substage. Eur Urol 2012, 61:378-384.
23. Bertz S., Denzinger S., Otto W., et al. Substaging by estimating the size of invasive tumour can improve risk stratification in pT1 urothelial bladder cancer-evaluation of a large hospital-based single-centre series. Histopathology 2011, 59:722-732.
24. Tilki D., Shariat S.F., Lotan Y., et al. Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage T1 disease and negative lymph nodes after radical cystectomy. BJU Int 2012, [Epub ahead of print].
25. Shariat S.F., Svatek R.S., Tilki D., et al. International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. BJU Int 2010, 105:1402-1412.
26. Segal R., Yafi F.A., Brimo F., et al. Prognostic factors and outcome in patients with T1 high-grade bladder cancer: can we identify patients for early cystectomy?. BJU Int 2012, 109:1026-1030.
27. van Rhijn B.W., Liu L., Vis A.N., et al. Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer. BJU Int 2012, 110:1169-1176.
28. Acikalin D., Oner U., Can C., et al. Predictive value of maspin and Ki-67 expression in transurethral resection specimens in patients with T1 bladder cancer. Tumori 2012, 98:344-350.
29. Quek M.L., Sanderson K., Daneshmand S., et al. New molecular markers for bladder cancer detection. Curr Opin Urol 2004, 14:259-264.
30. Esrig D., Elmajian D., Groshen S., et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994, 331:1259-1264.
31. Kim S.I., Kwon S.M., Kim Y.S., et al. Association of cyclooxygenase-2 expression with prognosis of stage T1 grade 3 bladder cancer. Urology 2002, 60:816-821.
32. Lopez-Knowles E., Hernandez S., Kogevinas M., et al. The p53 pathway and outcome among patients with T1G3 bladder tumors. Clin Cancer Res 2006, 12:6029-6036.
33. Shariat S.F., Zippe C., Ludecke G., et al. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder. J Urol 2005, 173:1518-1525.
34. deVere White R.W., Deitch A.D., Daneshmand S., et al. The prognostic significance of S-phase analysis in stage Ta/T1 bladder cancer. A Southwest Oncology Group Study. Eur Urol 2000, 37:595-600.
35. Jakse G., Algaba F., Malmstrom P.U., et al. A second-look TUR in T1 transitional cell carcinoma: why?. Eur Urol 2004, 45:539-546. [discussion: 546].
36. Miladi M., Peyromaure M., Zerbib M., et al. The value of a second transurethral resection in evaluating patients with bladder tumours. Eur Urol 2003, 43:241-245.
37. Schwaibold H.E., Sivalingam S., May F., et al. The value of a second transurethral resection for T1 bladder cancer. BJU Int 2006, 97:1199-1201.
38. Soloway M.S., Lee C.T., Steinberg G.D., et al. Difficult decisions in urologic oncology: management of high-grade T1 transitional cell carcinoma of the bladder. Urol Oncol 2007, 25:338-340.
39. Dalbagni G., Herr H.W., Reuter V.E. Impact of a second transurethral resection on the staging of T1 bladder cancer. Urology 2002, 60:822-824. [discussion: 824-5].
40. Herr H.W., Donat S.M., Dalbagni G. Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy?. J Urol 2007, 177:75-79. [discussion: 79].
41. Herr H.W. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy. J Urol 2005, 174:2134-2137.
42. Divrik R.T., Sahin A.F., Yildirim U., et al. Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial. Eur Urol 2010, 58:185-190.
43. Novara G., Ficarra V. Does routine second transurethral resection affect the long-term outcome of patients with T1 bladder cancer? Why a flawed randomized controlled trial cannot address the issue. Eur Urol 2010, 58:193-194.
44. Jauhiainen K., Alfthan O. Instillation of mitomycin C and doxorubicin in the prevention of recurrent superficial (Ta-T1) bladder cancer. Br J Urol 1987, 60:54-59.
45. Pansadoro V., Emiliozzi P., Defidio L., et al. Bacillus Calmette-Guerin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder: long-term results. J Urol 1995, 154:2054-2058.
46. Baniel J., Grauss D., Engelstein D., et al. Intravesical bacillus Calmette-Guerin treatment for stage T1 grade 3 transitional cell carcinoma of the bladder. Urology 1998, 52:785-789.
47. Lebret T., Gaudez F., Herve J.M., et al. Low-dose BCG instillations in the treatment of stage T1 grade 3 bladder tumours: recurrence, progression and success. Eur Urol 1998, 34:67-72.
48. Hurle R., Losa A., Manzetti A., et al. Intravesical bacille Calmette-Guerin in stage T1 grade 3 bladder cancer therapy: a 7-year follow-up. Urology 1999, 54:258-263.
49. Patard J., Moudouni S., Saint F., et al. Tumor progression and survival in patients with T1G3 bladder tumors: multicentric retrospective study comparing 94 patients treated during 17 years. Urology 2001, 58:551-556.
50. Kulkarni J.N., Gupta R. Recurrence and progression in stage T1G3 bladder tumour with intravesical bacille Calmette-Guerin (Danish 1331 strain). BJU Int 2002, 90:554-557.
51. Pansadoro V., Emiliozzi P., de Paula F., et al. Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guerin: 18-year experience. Urology 2002, 59:227-231.
52. Peyromaure M., Guerin F., Amsellem-Ouazana D., et al. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients. J Urol 2003, 169:2110-2112.
53. Shahin O., Thalmann G.N., Rentsch C., et al. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol 2003, 169:96-100. [discussion: 100].
54. Margel D., Tal R., Golan S., et al. Long-term follow-up of patients with stage T1 high-grade transitional cell carcinoma managed by Bacille Calmette-Guerin immunotherapy. Urology 2007, 69:78-82.
55. Cookson M.S., Sarosdy M.F. Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy. J Urol 1992, 148:797-801.
56. Eure G.R., Cundiff M.R., Schellhammer P.F. Bacillus Calmette-Guerin therapy for high risk stage T1 superficial bladder cancer. J Urol 1992, 147:376-379.
57. Mitra A.P., Quinn D.I., Dorff T.B., et al. Factors influencing post-recurrence survival in bladder cancer following radical cystectomy. BJU Int 2012, 109:846-854.
58. Lamm D.L., Blumenstein B.A., Crissman J.D., et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study. J Urol 2000, 163:1124-1129.
59. Zhang G.K., Uke E.T., Sharer W.C., et al. Reassessment of conservative management for stage T1N0M0 transitional cell carcinoma of the bladder. J Urol 1996, 155:1907-1909.
60. Herr H.W. Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome. Br J Urol 1997, 80:762-765.
61. Gohji K., Nomi M., Okamoto M., et al. Conservative therapy for stage T1b, grade 3 transitional cell carcinoma of the bladder. Urology 1999, 53:308-313.
62. Brake M., Loertzer H., Horsch R., et al. Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin. J Urol 2000, 163:1697-1701.
63. Iori F., Di Seri M., De Nunzio C., et al. Long-term maintenance bacille Calmette-Guerin therapy in high-grade superficial bladder cancer. Urology 2002, 59:414-418.
64. Griffiths T.R., Charlton M., Neal D.E., et al. Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance. J Urol 2002, 167:2408-2412.
65. Hara I., Miyake H., Takechi Y., et al. Clinical outcome of conservative therapy for stage T1, grade 3 transitional cell carcinoma of the bladder. Int J Urol 2003, 10:19-24.
66. McHugh L.A., Griffiths T.R. T1G3 transitional cell carcinoma of the bladder: recurrence, progression and survival. BJU Int 2004, 94:193.
67. Peyromaure M., Zerbib M. T1G3 transitional cell carcinoma of the bladder: recurrence, progression and survival. BJU Int 2004, 93:60-63.
68. Kulkarni G.S., Hakenberg O.W., Gschwend J.E., et al. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur Urol 2010, 57:60-70.
69. Sylvester R.J., van der M.A., Lamm D.L. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002, 168:1964-1970.
70. Herr H.W., Jakse G., Sheinfeld J. The T1 bladder tumor. Semin Urol 1990, 8:254-261.
71. Alkhateeb S.S., Van Rhijn B.W., Finelli A., et al. Nonprimary pT1 nonmuscle invasive bladder cancer treated with bacillus Calmette-Guerin is associated with higher risk of progression compared to primary T1 tumors. J Urol 2010, 184:81-86.
72. Kakiashvili D.M., van Rhijn B.W., Trottier G., et al. Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille Calmette-Guerin treatment. BJU Int 2011, 107:540-546.
73. Orsola A., Cecchini L., Raventos C.X., et al. Risk factors for positive findings in patients with high-grade T1 bladder cancer treated with transurethral resection of bladder tumour (TUR) and bacille Calmette-Guerin therapy and the decision for a repeat TUR. BJU Int 2010, 105:202-207.
74. Zieger K., Olsen P.R., Wolf H., et al. Long term follow-up of superficial invasive bladder carcinoma with or without concomitant epithelial atypia-recurrence and progression. Scand J Urol Nephrol 2002, 36:52-59.
75. Sylvester R.J., van der Meijden A.P., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006, 49. 466-77. [discussion: 475-7].
76. Raj G.V., Herr H., Serio A.M., et al. Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. J Urol 2007, 177:1283-1286. [discussion: 1286].
77. Kamat A.M., Dinney C.P., Gee J.R., et al. Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. Cancer 2007, 110:62-67.
78. Andius P., Johansson S.L., Holmang S. Prognostic factors in stage T1 bladder cancer: tumor pattern (solid or papillary) and vascular invasion more important than depth of invasion. Urology 2007, 70:758-762.
79. Lopez J.I., Angulo J.C. The prognostic significance of vascular invasion in stage T1 bladder cancer. Histopathology 1995, 27:27-33.
80. Weiss C., Wolze C., Engehausen D.G., et al. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy?. J Clin Oncol 2006, 24:2318-2324.
81. Harland S.J., Kynaston H., Grigor K., et al. A randomized trial of radical radiotherapy for the management of pT1G3 NXM0 transitional cell carcinoma of the bladder. J Urol 2007, 178:807-813. [discussion: 813].
82. Herr H.W., Sogani P.C. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?. J Urol 2001, 166:1296-1299.
83. Denzinger S., Fritsche H.M., Otto W., et al. Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach?. Eur Urol 2008, 53:146-152.
84. Hautmann R.E., Volkmer B.G., Gust K. Quantification of the survival benefit of early versus deferred cystectomy in high-risk non-muscle invasive bladder cancer (T1 G3). World J Urol 2009, 27:347-351.
85. Dalbagni G., Vora K., Kaag M., et al. Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer. Eur Urol 2009, 56:903-910.
86. Amling C.L., Thrasher J.B., Frazier H.A., et al. Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder. J Urol 1994, 151:31-35. [discussion: 35-6].
87. Thalmann G.N., Markwalder R., Shahin O., et al. Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy?. J Urol 2004, 172:70-75.
88. Gupta A., Lotan Y., Bastian P.J., et al. Outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma treated with radical cystectomy. Urology 2008, 71:302-307.
89. Wiesner C., Pfitzenmaier J., Faldum A., et al. Lymph node metastases in non-muscle invasive bladder cancer are correlated with the number of transurethral resections and tumour upstaging at radical cystectomy. BJU Int 2005, 95:301-305.
90. Masood S., Mufti G.R. Outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma treated with radical cystectomy. Urology 2008, 72:952. [author reply: 952].
91. Fritsche H.M., Burger M., Svatek R.S., et al. Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol 2010, 57:300-309.
92. Pagano F., Bassi P., Galetti T.P., et al. Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification. J Urol 1991, 145:45-50.
93. Stein J.P., Lieskovsky G., Cote R., et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001, 19:666-675.
94. Madersbacher S., Hochreiter W., Burkhard F., et al. Radical cystectomy for bladder cancer today-a homogeneous series without neoadjuvant therapy. J Clin Oncol 2003, 21:690-696.
95. Hautmann R.E., de Petriconi R.C., Pfeiffer C., et al. Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur Urol 2012, 61:1039-1047.
96. Shariat S.F., Karakiewicz P.I., Palapattu G.S., et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol 2006, 176:2414-2422. [discussion: 2422].
97. Canter D., Egleston B., Wong Y.N., et al. Use of radical cystectomy as initial therapy for the treatment of high-grade T1 urothelial carcinoma of the bladder: A SEER database analysis. Urol Oncol 2011, [Epub ahead of print].
98. Chalasani V., Kassouf W., Chin J.L., et al. Radical cystectomy for the treatment of T1 bladder cancer: the Canadian Bladder Cancer Network experience. Can Urol Assoc J 2011, 5:83-87.
99. Stein J.P., Penson D.F. Invasive T1 bladder cancer: indications and rationale for radical cystectomy. BJU Int 2008, 102:270-275.
100. Nieder A.M., Brausi M., Lamm D., et al. Management of stage T1 tumors of the bladder: International Consensus Panel. Urology 2005, 66:108-125.
101. Bostrom P.J., Alkhateeb S., van Rhijn B.W., et al. Optimal timing of radical cystectomy in T1 high-grade bladder cancer. Expert Rev Anticancer Ther 2010, 10:1891-1902.
102. Solsona E., Iborra I., Rubio J., et al. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour. BJU Int 2004, 94:1258-1262.
103. Nieder A.M., Simon M.A., Kim S.S., et al. Radical cystectomy after bacillus Calmette-Guerin for high-risk Ta, T1, and carcinoma in situ: defining the risk of initial bladder preservation. Urology 2006, 67:737-741.
104. Ahmadi H., Mitra A.P., Abdelsayed G.A., et al. Principal component analysis based pre-cystectomy model to predict pathological stage in patients with clinical organ-confined bladder cancer. BJU Int 2012, [Epub ahead of print].
105. Herr H.W., Donat S.M. A re-staging transurethral resection predicts early progression of superficial bladder cancer. BJU Int 2006, 97:1194-1198.
106. Brauers A., Buettner R., Jakse G. Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy often too early?. J Urol 2001, 165:808-810.
107. Brausi M., Witjes J.A., Lamm D., et al. A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol 2011, 186:2158-2167.
108. Hautmann R.E., Abol-Enein H., Hafez K., et al. Urinary diversion. Urology 2007, 69:17-49.
109. Ahmadi H., Skinner E.C., Simma-Chiang V., et al. Urinary functional outcome following radical cystoprostatectomy and ileal neobladder reconstruction in male patients. J Urol 2012, [Epub ahead of print].
110. Puppo P., Introini C., Bertolotto F., et al. Potency preserving cystectomy with intrafascial prostatectomy for high risk superficial bladder cancer. J Urol 2008, 179:1727-1732. [discussion: 1732].
111. Hekal I.A., El-Bahnasawy M.S., Mosbah A., et al. Recoverability of erectile function in post-radical cystectomy patients: subjective and objective evaluations. Eur Urol 2009, 55:275-283.
112. Kulkarni G.S., Finelli A., Fleshner N.E., et al. Optimal management of high-risk T1G3 bladder cancer: a decision analysis. PLoS Med 2007, 4:e284.